Yuichi Ando

576 total citations
47 papers, 301 citations indexed

About

Yuichi Ando is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yuichi Ando has authored 47 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Yuichi Ando's work include Cancer Immunotherapy and Biomarkers (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Esophageal Cancer Research and Treatment (6 papers). Yuichi Ando is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Esophageal Cancer Research and Treatment (6 papers). Yuichi Ando collaborates with scholars based in Japan, United States and Switzerland. Yuichi Ando's co-authors include Osamu Maeda, Hironobu Minami, Shunji Takahashi, Satoshi Nishiwaki, Tomoyuki Kakizume, Naomi Kiyota, Satoru Iwasa, Naoko Suenaga, Cornelia Quadt and Yasuhide Yamada and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Yuichi Ando

41 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuichi Ando Japan 9 130 119 76 32 32 47 301
Leonardo Rojas Colombia 10 147 1.1× 72 0.6× 151 2.0× 26 0.8× 18 0.6× 40 268
Ana B. Galván Spain 9 112 0.9× 81 0.7× 138 1.8× 34 1.1× 41 1.3× 13 307
D. Viñal Spain 10 166 1.3× 88 0.7× 90 1.2× 25 0.8× 45 1.4× 33 285
Laura Mansi France 12 228 1.8× 85 0.7× 94 1.2× 22 0.7× 57 1.8× 30 373
Thilo Zander Switzerland 10 143 1.1× 95 0.8× 112 1.5× 14 0.4× 22 0.7× 25 308
Carmen G. Rea Italy 7 207 1.6× 92 0.8× 143 1.9× 23 0.7× 20 0.6× 15 322
Zijun Zhen China 12 155 1.2× 103 0.9× 60 0.8× 47 1.5× 74 2.3× 62 389
Hari A. Deshpande United States 10 136 1.0× 120 1.0× 90 1.2× 57 1.8× 16 0.5× 46 363
Jake Allred United States 8 258 2.0× 55 0.5× 57 0.8× 27 0.8× 32 1.0× 13 373

Countries citing papers authored by Yuichi Ando

Since Specialization
Citations

This map shows the geographic impact of Yuichi Ando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichi Ando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichi Ando more than expected).

Fields of papers citing papers by Yuichi Ando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichi Ando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichi Ando. The network helps show where Yuichi Ando may publish in the future.

Co-authorship network of co-authors of Yuichi Ando

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichi Ando. A scholar is included among the top collaborators of Yuichi Ando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichi Ando. Yuichi Ando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mizuno, Kazuyuki, Takafumi Yamamoto, Takanori Ito, et al.. (2025). Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies. Digestive and Liver Disease. 57(6). 1230–1237. 1 indexed citations
2.
Maeda, Osamu, et al.. (2025). Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors. Cancer Science. 116(4). 1107–1114.
3.
Nishida, Kazuki, et al.. (2025). Pazopanib and antacids: insights from the WHO pharmacovigilance database. Cancer Chemotherapy and Pharmacology. 95(1). 66–66. 1 indexed citations
4.
Mizuno, Kazuyuki, Osamu Maeda, & Yuichi Ando. (2025). Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review. Japanese Journal of Clinical Oncology. 56(2). 117–129. 1 indexed citations
5.
Kato, Taigo, et al.. (2024). Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review. Cancer Diagnosis & Prognosis. 4(4). 390–395. 2 indexed citations
6.
7.
Takano, Yuko, Tomoya Shimokata, Hiroshi Urakawa, Toyone Kikumori, & Yuichi Ando. (2024). Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAF V600E mutation. International Cancer Conference Journal. 13(3). 184–188.
8.
Maeda, Osamu, Mitsuro Kanda, Dai Shimizu, et al.. (2024). Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer. Cancer Medicine. 13(2). e6974–e6974. 3 indexed citations
9.
Nakanishi, Koki, Chie Tanaka, Mitsuro Kanda, et al.. (2023). Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer. Cancers. 15(21). 5197–5197. 3 indexed citations
10.
Liang, Yao, Osamu Maeda, Tomoya Shimokata, et al.. (2023). Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma. International Cancer Conference Journal. 13(1). 63–67. 1 indexed citations
11.
Yamamoto, Takafumi, Takanori Ito, Masatoshi Ishigami, et al.. (2022). Clustering using unsupervised machine learning to stratify the risk of immune‐related liver injury. Journal of Gastroenterology and Hepatology. 38(2). 251–258. 8 indexed citations
12.
Kazama, S., Ryota Morimoto, Yuki Kimura, et al.. (2021). Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardio-Oncology. 7(1). 26–26. 4 indexed citations
13.
Schöffski, Patrick, Nicole Concin, Cristina Suárez, et al.. (2021). A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncology Research and Treatment. 44(10). 547–556. 19 indexed citations
14.
Minami, Hironobu, Toshihiko Doi, Masanori Toyoda, et al.. (2020). Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies. Cancer Science. 112(2). 725–733. 6 indexed citations
15.
Nishiwaki, Satoshi & Yuichi Ando. (2020). Gap between pediatric and adult approvals of molecular targeted drugs. Scientific Reports. 10(1). 17145–17145. 11 indexed citations
16.
Ogura, Atsushi, Keisuke Uehara, Norifumi Hattori, et al.. (2020). What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?. International Journal of Colorectal Disease. 35(11). 2073–2080. 3 indexed citations
17.
Maeda, Osamu & Yuichi Ando. (2019). Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World Journal of Gastrointestinal Oncology. 11(7). 518–526. 6 indexed citations
18.
Shimokata, Tomoya, Koichiro Watanabe, Takashi Shibata, et al.. (2013). Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors. 2 indexed citations
19.
Morita, Sachi, Satoshi Oizumi, Hironobu Minami, et al.. (2011). Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. Investigational New Drugs. 30(5). 1950–1957. 36 indexed citations
20.
Hondo, Ryo, Seiji Itoh, Kenji Kikuchi, et al.. (1996). TITRATION OF HUMAN CYTOMEGALOVIRUS (HCMV) DNA IN URINE BY COMBINED USE OF PCR AND MICROPLATE HYBRIDIZATION IN A RENAL TRANSPLANT PATIENT WITH HCMV PNEUMONITIS. Japanese Journal of Medical Science and Biology. 49(3). 121–127. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonardo Rojas Breakdown of academic impact, for papers by Ana B. Galván Breakdown of academic impact, for papers by D. Viñal Breakdown of academic impact, for papers by Laura Mansi Breakdown of academic impact, for papers by Thilo Zander Breakdown of academic impact, for papers by Carmen G. Rea Breakdown of academic impact, for papers by Zijun Zhen Breakdown of academic impact, for papers by Hari A. Deshpande Breakdown of academic impact, for papers by Jake Allred
Rankless by CCL
2026